Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.40 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.36 |
| ▸ | TK2 | O00142 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5531485 | 1.00 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY12 | |
| SCHEMBL4083099 | 1.00 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY12 | |
| SCHEMBL4081760 | 0.79 | NT5E (0.39) | P2RY12P2RY2P2RY4 | |
| SCHEMBL9069521 | 0.78 | P2RY2 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY12 | |
| SCHEMBL23522590 | 0.78 | P2RY2 (0.38) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY12 | |
| SCHEMBL9556690 | 0.78 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL3760060 | 0.77 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL564852 | 0.75 | P2RY12 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY12 | |
| SCHEMBL6224763 | 0.75 | P2RY2 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL5547202 | 0.74 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507859-B2 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1644479-A4 | FUNCTIONAL SYNTHETIC MOLECULES AND MACROMOLECULES FOR GENE DELIVERY | GRINSTAFF MARK W (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20060241071-A1 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC | 2006-10-26 | — | — | US | disclosed |
| EP-1644479-A2 | FUNCTIONAL SYNTHETIC MOLECULES AND MACROMOLECULES FOR GENE DELIVERY | Grinstaff, Mark, W. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005007810-A2 | FUNCTIONAL SYNTHETIC MOLECULES AND MACROMOLECULES FOR GENE DELIVERY | GRINSTAFF MARK W (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241071-A1 | Functional synthetic molecules and macromolecules for gene delivery | ANXA6, STING1, POLRMT | SLC28A1 1592/4885SLC28A2 1890/4885SLC29A1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.